Project Grant HT94252310768
Award Date 9/1/23
Completion Date 8/31/27
Dollars Obligated $2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
- The University of Cambridge received a $4,598,677 Project Grant from the Defense Health Agency to conduct research under the Military Medical Research and Development program (CFDA 12.420). The research aims to use multi-modal data integration across breast cancer molecular subtypes to develop predictors of treatment response, early relapse, and survival, as well as explore early signals of later metastatic recurrence. The 4-year grant, which began on September 1, 2023, leverages the...
- The University of Cambridge received a $842,452 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on May 1, 2024. The grant supports research to decode the mechanisms of genomic instability in triple-negative breast cancer (TNBC) and how they impact the tissue microenvironment and therapy response at metastatic sites. This 3-year project aims to advance understanding of TNBC biology and identify new therapeutic targets....
- The University of Cambridge received a $824,548 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding the role of hypoxia in vasculogenic mimicry, response to therapy, and metastasis. This 3-year grant awarded on May 1, 2024 will support basic, translational, and clinical research to advance scientific understanding and develop new treatments in areas such as cancer, neurological...
- The U.S. Defense Health Agency awarded King's College London a $1,712,517 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to identify molecular predictors of risk and validate the evolution of ductal carcinoma in situ (DCIS) over a 4-year period ending on September 29, 2027. As the prime awardee, King's College London will leverage its expertise in biomedical research to advance the scientific understanding of breast cancer progression. This award supports...
- The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
- The Department of Defense's Defense Health Agency awarded a $4,818,759 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the project "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant, awarded on April 1, 2024, will fund research to improve understanding and treatment of lethal breast cancers through advanced single-cell and spatial analysis techniques. This work supports the program's goals of...
- The Department of the Army Medical Command awarded a $699,534 project grant to the Institute of Cancer Research: Royal Cancer Hospital under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will support research on B7-H3 (CD276) as a therapeutic target in lethal prostate cancers. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research that investigates medical solutions...
- The University of Massachusetts Amherst was awarded a $557,247 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from February 1, 2023 to January 31, 2026 to develop intracellular bacterial delivery of vaccine antigens to establish T-cell antitumor immunity in triple-negative breast cancer. The Military Medical Research and Development program supports innovative medical research with...
- This federal Project Grant award of $299,999.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding research at the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The award aims to enhance the efficacy of BH3 mimetics, a class of cancer therapeutic drugs, to induce apoptosis (programmed cell death) in lethal prostate cancer. The performance period for this award is June 1, 2024 through May 31, 2026. As a...
- The Defense Health Agency awarded Duke University a $3,811,150.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct a research project titled "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant period runs from April 1, 2024 to March 31, 2028. The key products and services to be delivered under this award include comprehensive single-cell and spatial analysis of breast cancer samples to characterize tumor heterogeneity...